Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine

A Phase II Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Treated With Gemcitabine Followed by Brentuximab Vedotin Maintenance

This study is an open label, multicenter phase 2 study. The primary objective of the study is to determine the efficacy of brentuximab vedotin in patients treated by gemcitabine for relapsed or refractory peripheral T-cell lymphoma in term of overall response rate assessed after 4 cycles of treatment according to the international response criteria for malignant lymphoma (Lugano Classification 2014 - CT-Based Response).

Study Overview

• Status: Completed
• Conditions: Refractory Peripheral T-Cell Lymphoma; Relapsed Peripheral T-Cell Lymphoma
• Intervention / Treatment: Drug: Brentuximab Vedotin - induction; Drug: Gemcitabine; Drug: Brentuximab Vedotin - maintenance; Procedure: autologous or allogeneic stem cell transplantation

Detailed Description

Currently, there is no standard treatment for patients with recurrent or refractory peripheral T-cell lymphoma who relapse after a first line of cyclophosphamide, hydroxydaunomycin, oncovin, and prednisone (CHOP) treatment.

Chemotherapies such as gemcitabine are used as monotherapy but the results alone are insufficient. In addition, there is no approved monotherapy in the European Union, with the exception of brentuximab vedotin in refractory or recurrent large systemic anaplastic lymphomas.

Stem cell transplantation may be an option for patients who respond to a second line of treatment or a subsequent line of treatment, but conditions for being eligible for transplantation, including long-term remission, are infrequent.

Brentuximab vedotin (BV) is a targeted treatment directed against a protein, cluster of differentiation antigen 30 (CD30), present on the surface of lymphoma cells. It allows chemotherapy to enter directly into the lymphoma cell. The CD30 protein is variably expressed in patients with relapsed or refractory T-cell lymphoma; about 50% of patients have significant expression.

Data from clinical studies with brentuximab vedotin suggest that the addition of this treatment to gemcitabine may be more successful than gemcitabine alone.

The main hypothesis is a 15% increase in responder patients after 4 cycles of treatment with brentuximab vedotin and gemcitabine. The main objective of the study is therefore to determine the overall response rate after 4 cycles of treatment according to the criteria of Lugano 2014 (response based on CT-scan).

The secondary objectives will focus on the efficacy of brentuximab vedotin: complete response rate, response time for responder patients, time to failure of treatment, time to next treatment and overall survival, efficacy of brentuximab vedotin maintenance: survival progression-free, response time, overall survival, overall response rate based on positron emission tomography (PET)-scan and brentuximab vedotin toxicity in patients treated with gemcitabine and in maintenance therapy.

The duration of the study is estimated to be 4.5 years including follow-up with an estimated recruitment period of 1.5 years. 70 patients will be enrolled.

• Study Type: Interventional
• Enrollment (Actual): 71
• Phase: Phase 2

Contacts and Locations

Study Locations

• Belgium
  • Antwerpen, Belgium, 2060
    • ZNA Stuivenberg
  • Bruges, Belgium, 8000
    • A. Z. Sint-Jan
  • Brussels, Belgium
    • Institut Jules Bordet
  • Brussels, Belgium, 1200
    • Clinique Universitaire Saint Luc
  • Brussels, Belgium
    • ULB Hopital Erasme
  • Gent, Belgium, 9000
    • UZ Gent
  • Liege, Belgium, 4000
    • CHU de Liège
  • Yvoir, Belgium
    • Chu Ucl Namur
• France
  • Amiens, France, 80054
    • IHBN - CHU Côte de Nacre
  • Amiens, France
    • CHU d'AMIENS
  • Angers, France, 49033
    • CHU Angers
  • Avignon, France, 84000
    • CH d'Avignon - Hôpital Henri Dufaut
  • Bayonne, France, 64100
    • CH Côte Basque
  • Besançon, France, 25030
    • CHU de Besancon - Hopital Jean Minjoz
  • Chambery, France, 73011
    • CH Chambery
  • Clermont-Ferrand, France, 63000
    • CHU d'Estaing
  • Creteil, France, 94010
    • APHP - Hopital Henri Mondor
  • Dijon, France, 21000
    • CHU de Dijon - Hopital le Bocage
  • Grenoble, France, 38043
    • CHU Grenoble
  • Le Chesnay, France, 78157
    • Ch de Versailles - Hopital Andre Mignot
  • Le Mans, France, 72000
    • CH du Mans
  • Lille, France
    • CHRU de Lille - Hopital Claude Huriez
  • Limoges, France
    • CHU de Limoges
  • Lyon Cedex 8, France, 69373
    • Centre Leon Berard
  • Metz-Tessy, France, 74374
    • Centre Hospitalier Annecy Genevois
  • Montpellier, France, 34295
    • CH Saint-Eloi
  • Mulhouse, France, 68070
    • CH de Mulhouse Sud Alsace
  • Nancy, France, 54511
    • CHU Nancy - Brabois
  • Nantes, France, 44093
    • CHU de Nantes - Hotel Dieu
  • Paris, France, 75015
    • APHP - Hôpital Necker
  • Paris Cedex 10, France, 75475
    • APHP - Hôpital Saint Louis
  • Pessac, France, 33604
    • Centre François Magendie - Hôpital du Haut Lévêque
  • Pierre Bénite, France, 69495
    • Centre Hospitalier Lyon Sud
  • Poitiers, France, 86021
    • CHU de Poitiers - Hôpital de La Milétrie
  • Rennes, France, 35033
    • CHU de Rennes
  • Rouen, France, 76038
    • Centre Henri Becquerel
  • Toulouse, France, 31059
    • CHU de Toulouse
  • Tours, France, 37044
    • Chru De Tours
  • Valenciennes, France, 59322
    • Ch de Valenciennes

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Males and females of 18 years to 80 years of age;
• Understand and voluntarily sign an informed consent document prior to any study related assessment or procedure;
• Patients able to adhere to the study visit schedule and protocol requirements;
• Patients with histologically proven, CD30 positive (at least 5% of cells according to local examination) peripheral T-cell lymphoma (PTCL) according to the 2016 World Health Organization (WHO) classification for whom gemcitabine treatment is expected. A biopsy at relapse is highly recommended;
• Patients who have evidence of relapsed disease after at least one line (and no more than three lines) of treatment or who were refractory to a first or subsequent line of treatment;
• Patients with Ann Arbor stage I - IV;
• Patients with Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2;
• Patients with at least one measurable disease, i.e. one nodal or extra-nodal lesion of 1.5 cm or more;
• Negative pregnancy test for females of childbearing potential (FCBP);
• Female patients of child bearing potential must use an effective method of birth control (i.e. hormonal contraceptive, intrauterine device, diaphragm with spermicide, condom with spermicide or abstinence) during treatment period and 6 months thereafter.
• Males must use an effective method of birth control during treatment period and 6 months thereafter.

Exclusion Criteria:

• Any significant medical condition or laboratory abnormality unrelated to PTCL, or psychiatric illness that would prevent the patient from participating in the study and from signing the informed consent form;
• Any condition that confounds the ability to interpret data from the study;
• Other types of lymphomas, e.g. B-cell lymphoma;
• Central nervous system and/or meningeal involvement by PTCL;
• Signs or symptoms of Progressive Multifocal Leukoencephalopathy;
• Preexistent peripheral neuropathy ≥ grade 2, whatever the cause;
• Contraindication to any drug contained in the chemotherapy regimen;
• Known hypersensitivity to recombinant proteins, murine proteins, or to any excipient contained in the drug formulation of brentuximab vedotin;
• Subjects with HIV or HTLV1 positivity;
• Subjects with active hepatitis B or C. Chronic carriers of hepatitis B without hepatitis B virus (HBV) DNA positive blood are eligible. Subjects with non-active hepatitis C (with normal transaminases) are eligible;
• Chronic or acute, clinically significant, untreated bacterial, viral or fungal infection;

• Any of the following laboratory abnormalities:

  1. Absolute neutrophil count (ANC) < 1500 cells/mm3 (1.5 x 109/L);
  2. Platelet count <75,000/mm3 (75 x 109/L);
  3. Serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥ 3.0 x upper limit of normal (ULN). AST or ALT may be elevated up to 5 x ULN if their elevation can be ascribed to the presence of hematologic/solid tumor in the liver;
  4. Serum total bilirubin > 1.5 x ULN;
  5. Serum lipase level > 2 x ULN;
  6. Serum creatinine > 2.0 mg/dL and/or creatinine clearance or calculated creatinine clearance < 40 mL/minute;
  7. Hemoglobin < 8g/dL;
• Active malignancies other than PTCL requiring systemic treatment;
• Previous treatment with brentuximab vedotin;
• Previous treatment with gemcitabine;
• Pregnant or lactating females or women of childbearing potential not willing to use an adequate method of birth control for the duration of the study;

• Known history of any of the following cardiovascular conditions:

  1. Myocardial infarction within 2 years of enrollment
  2. New York Heart Association (NYHA) Class III or IV heart failure
  3. Evidence of current uncontrolled cardiovascular conditions, including cardiac arrhythmias, congestive heart failure (CHF), angina, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities
  4. Recent evidence (within 6 months before first dose of study drug) of a left-ventricular ejection fraction <50%
• Patients that have not completed any prior treatment chemotherapy and/or other investigational agents within at least 5 half-lives of last dose of that prior treatment;
• Diagnosed or treated for another malignancy within 3 years before the first dose or previously diagnosed with another malignancy and have evidence of residual disease. Patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Experimental; Patients treated with gemcitabine will receive Brentuximab Vedotin-induction for 4 cycles of induction. Patients who will obtain partial or complete response and who will be eligible for transplant will receive autologous or allogeneic stem cell transplantation. Patients who will obtain partial or complete response and who will not be eligible for transplant will receive maintenance therapy with Brentuximab Vedotin-maintenance every 3 weeks for 12 infusions.

Drug: Brentuximab Vedotin - induction; Brentuximab vedotin 1.8 mg/kg at D8 of a 28-day cycle - 4 cycles = 16 weeks for combined chemotherapy; Other Names: Adcetris; Drug: Gemcitabine; Gemcitabine 1000 mg/m² at D1 and D15 of a 28-day cycle - 4 cycles = 16 weeks for combined chemotherapy; Other Names: Gemzar; Drug: Brentuximab Vedotin - maintenance; Patients who will obtain partial or complete response and who will not be eligible for transplant will receive maintenance therapy with brentuximab vedotin every 3 weeks for 12 infusions. Brentuximab vedotin 1.8 mg/kg at D1 of a 21-day cycle - 12 cycles = 36 weeks for maintenance therapy; Other Names: Adcetris; Procedure: autologous or allogeneic stem cell transplantation; Patients who will obtain partial or complete response and who will be eligible for transplant will receive autologous or allogeneic stem cell transplantation

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall Response Rate (ORR)	rate of patient in Complete/Partial response according to the international response criteria for malignant lymphoma (Lugano Classification 2014 - CT-Based Response).	16 weeks = 4 cycles or permanent treatment discontinuation

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression-Free Survival (PFS)	% of patient who did not progressed according to the international response criteria for malignant lymphoma (Lugano Classification 2014 - CT-Based Response).	16 weeks = 4 cycles or permanent treatment discontinuation
Progression-Free Survival (PFS)	% of patient who did not progressed according to the international response criteria for malignant lymphoma (Lugano Classification 2014 - CT-Based Response).	4.5 years
Complete Response Rate (CRR)	rate of patient in Complete Response (CR)according to the international response criteria for malignant lymphoma (Lugano Classification 2014 - CT-Based Response).	16 weeks = 4 cycles or permanent treatment discontinuation
Duration of Response (DoR)	duration between the Complete/Partial Response and the Progression according to the international response criteria for malignant lymphoma (Lugano Classification 2014 - CT-Based Response) = duration between the Complete/Partial Response and the Progression	16 weeks = 4 cycles or permanent treatment discontinuation
Duration of Response (DoR)	duration between the Complete/Partial Response and the Progression according to the international response criteria for malignant lymphoma (Lugano Classification 2014 - CT-Based Response) = duration between the Complete/Partial Response and the Progression	4.5 years
Time to Treatment Failure (TTF)	duration between the inclusion and the premature end of treatment	16 weeks = 4 cycles or permanent treatment discontinuation
Time to next treatment	Duration between the end of the studied treatment and the beginning of a new one after progression	16 weeks = 4 cycles or permanent treatment discontinuation
Overall Survival (OS)	% of patient still alive	16 weeks = 4 cycles or permanent treatment discontinuation
Overall Survival (OS)	% of patient still alive	4.5 years
Overall response rate	rate of patient in Complete/Partial response according to the international response criteria for malignant lymphoma (Lugano Classification 2014 - CT-Based Response).	4.5 years
Number of Serious Adverse Events (SAE) during the induction period		16 weeks = 4 cycles or permanent treatment discontinuation
Number of Serious Adverse Events (SAE) during the maintenance period		36 weeks = 12 cycles or permanent treatment discontinuation

Collaborators and Investigators

• Sponsor: The Lymphoma Academic Research Organisation
• Investigators: Study Chair: Richard DELARUE, MD, APHP - Hôpital Necker; Study Chair: Olivier TOURNILHAC, MD, CHU Estaing - Clermont Ferrant

Publications and helpful links

Helpful Links

• Website of LYSARC

Study record dates

Study Major Dates

• Study Start (Actual): April 10, 2018
• Primary Completion (Actual): January 31, 2020
• Study Completion (Actual): October 8, 2022

Study Registration Dates

• First Submitted: April 5, 2018
• First Submitted That Met QC Criteria: April 5, 2018
• First Posted (Actual): April 12, 2018

Study Record Updates

• Last Update Posted (Actual): July 30, 2025
• Last Update Submitted That Met QC Criteria: July 28, 2025
• Last Verified: July 1, 2025

More Information

Terms related to this study

• Keywords: T-cell lymphoma; Brentuximab Vedotin
• Additional Relevant MeSH Terms: Neoplasms; Immune System Diseases; Neoplasms by Histologic Type; Lymphatic Diseases; Lymphoproliferative Disorders; Immunoproliferative Disorders; Lymphoma, Non-Hodgkin; Lymphoma; Lymphoma, T-Cell; Lymphoma, T-Cell, Peripheral; Antineoplastic Agents, Immunological; Antineoplastic Agents; Immunologic Factors; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Antimetabolites, Antineoplastic; Antimetabolites; Immunoconjugates; Immunotoxins; Brentuximab Vedotin; Gemcitabine; Antibodies, Monoclonal
• Other Study ID Numbers: TOTAL

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No